Evidence map›Paper›PMID 40006626›Full record

ArticlePharmaceutics2025

Preclinical Long-Term Stability and Forced Degradation Assessment of EPICERTIN, a Mucosal Healing Biotherapeutic for Inflammatory Bowel Disease.

Wendy M Kittle, Micaela A Reeves, Ashley E Fulkerson, Krystal T Hamorsky, David A Morris, Kathleen T Kitterman, Michael L Merchant, Nobuyuki Matoba

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wendy M KittleDepartment of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Micaela A ReevesDepartment of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Ashley E FulkersonBrown Cancer Center, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Krystal T HamorskyBrown Cancer Center, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
David A MorrisCenter for Predictive Medicine, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Kathleen T KittermanCenter for Predictive Medicine, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Michael L MerchantDepartment of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Nobuyuki MatobaDepartment of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.ORCID 0000-0001-7231-3004

Funding

Preclinical validation of oral therapeutic lead proteins targeting epithelial GM1 ganglioside for ulcerative colitis therapyR01DK123712 · NIDDK · UNIVERSITY OF LOUISVILLE · PI MATOBA, NOBUYUKI · 2020 to 2023
$1.8M
Leona M. and Harry B. Helmsley Charitable Trust 2014PG-MED001NIDDK NIH HHS R01 DK123712
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biopharmaceuticalscholera toxin B subunitdrug developmentEPICERTINforced degradationinflammatory bowel diseaselong-term stability

Identifiers

PMID40006626
PMCPMC11859197

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.